“Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study”, Clinics, vol. 67, no. 3, pp. 283–287, Jan. 2012, doi: 10.6061/clinics/2012(03)14.